Abstracts tagged "Abatacept and juvenile idiopathic arthritis (JIA)"

Abstract Number: 1446 • 2015 ACR/ARHP Annual Meeting
Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Interim Results from the Abatacept in JIA Registry
Daniel J Lovell¹, N Ruperto², S Spalding³, JA Dare⁴, R Cimaz⁵, V Stanevica⁶, RK Vehe⁷, N Tzaribachev⁸, G Horneff⁹, M Trachana¹⁰, TA Simon¹¹, HI Brunner¹² and A Martini², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Istituto G. Gaslini Pediatria II Reumatologia, Genova, Italy, ³Cleveland Clinic, Cleveland, OH, ⁴University of Arkansas Medical Center, Little Rock, AR, ⁵Azienda Ospedaliero-Universitaria Meyer, Florence, Italy, ⁶Riga Stradins University, Riga, Latvia, ⁷University of Minnesota, Minneapolis, MN, ⁸Pediatric Rheumatology, Bad Bramstedt, Germany, ⁹Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ¹⁰Hippokration General Hospital, Thessaloniki, Greece, ¹¹Bristol-Myers Squibb, Hopewell, NJ, ¹²Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Abatacept (ABA) is a widely approved and used biologic in children with juvenile idiopathic arthritis (JIA). The purpose of this study was to describe…
Abstract Number: 1676 • 2012 ACR/ARHP Annual Meeting
Abatacept As First Line Biological Treatment for Severe Juvenile Idiopathic Arthritis-Related Uveitis. A Multicenter Study
Carolina Birolo¹, Maria Elisabetta Zannin², Svetlana Arsenyeva³, Rolando Cimaz⁴, Elisabetta Miserocchi⁵, Margarita Dubko⁶, Chantal Deslandre⁷, Fernanda Falcini⁸, Maria Alessio⁹, Francesco La Torre¹⁰, Ekaterina Denisova¹¹, Irina Nikishina¹² and Francesco Zulian¹³, ¹Department of Pediatrics, Rheumatology Unit, University of Padua, Padua, Italy, ²Department of Pediatrics, Ophthalmology Unit, University of Padua, Padua, Italy, ³Pediatric Department, Scientific Research Institute of Rheumatology RAMS, Moskow, Russia, ⁴Rheumatology Unit, A. Meyer Children's Hospital, Florence, Italy, ⁵Department of Ophthalmology, Scientific Institute San Raffaele, University Vita-Salute, Milan, Italy, ⁶State Pediatric Medical University, Saint-Petersburg, Russia, ⁷Rheumatology, Cochin Hospital, Paris, France, ⁸Department of Biomedicine, Division of Rheumatology AOUC, Excellence Centre for Research, Florence, Italy, ⁹Department of Pediatrics, Rheumatology Unit, University of Naples Federico II, Naples, Italy, ¹⁰DIMIMP-University, Rheumatologic Section, Bari, Italy, ¹¹Helmgoltz Moscow Recearch Institute of Eye Diseases, Moskow, Russia, ¹²Pediatric Department, Scientific Research Institute of Rheumatology RAMS, Moskow, Moskow, Russia, ¹³Department of Pediatrics, University of Padua, Padova, Italy
Background/Purpose: Anterior uveitis is a serious complication of Juvenile Idiopathic Arthritis (JIA). Recently, Abatacept (ABA) has been used in children with JIA-uveitis who had failed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].